Navigation Links
Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
Date:9/24/2010

rol of sales and marketing of Enablex for the U.S. market, and expects to assume manufacturing control for the U.S. within three years.

Prior to this announcement, Warner Chilcott co-promoted Enablex with Novartis in the U.S. pursuant to an agreement that it assumed upon its purchase of the global branded prescription pharmaceuticals business of The Procter & Gamble Company in October 2009.  Under the terms of the co-promotion agreement, Warner Chilcott and Novartis shared development and promotion costs relating to the U.S. Enablex business and Warner Chilcott received a contractual percentage of Novartis' sales of Enablex in the U.S., which Warner Chilcott recorded on a net basis in "other revenue".  Under that agreement, Warner Chilcott was also obligated to incur an agreed upon amount for advertising, promotion and selling costs each fiscal year.  Following completion of the transaction, Warner Chilcott will recognize all sales of Enablex in the U.S. as revenues, as well as all expenses relating to such sales.  The Company expects this transaction will have a modestly accretive impact on the Company's 2010 adjusted cash net income and adjusted cash net income per share following the closing.

Enablex was approved by the U.S. Food and Drug Administration in 2004 for the treatment of overactive bladder, and launched in 2005.

About Warner Chilcott Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets.  The Company is fully integrated with internal resources dedicated to the development, manufacturing and promotion of its products.  WCRX-F.

Forward Looking Statements This press release contains forward-looking statements concerning our operations, our anticipated financial performance and financial condition, and our business plans
'/>"/>

SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Warner Chilcott Announces $500 Million Senior Notes Offering in Connection With Agreement to Acquire U.S. Rights to Enablex®
2. Warner Chilcott to Present at UBS Global Life Sciences Conference
3. Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
4. Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance
5. Warner Chilcott Announces Earnings Release Date and Conference Call for Second Quarter 2010 Financial Results
6. Warner Chilcott Announces 3-Month Extension of PDUFA Date on Next Generation Actonel Product
7. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
8. Warner Chilcott to Present at the Wells Fargo Securities Healthcare Conference
9. Warner Chilcott to Present at the Bank of America Merrill Lynch Healthcare Conference
10. Warner Chilcott Announces Earnings Release Date and Conference Call For First Quarter 2010 Financial Results
11. Warner Chilcott Announces 2010 Financial Guidance Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 21, 2014 Influenza will affect as many ... the United States as high as ... to spread is from person to person in respiratory droplets ... serve way of death, but kills much fewer people each ... done by human fluids including sweat, saliva, blood and other ...
(Date:10/22/2014)... and AUSTIN, Texas , Oct. ... LLC today announced they have entered into a ... immunotherapies designed to target cancers. PhosImmune ... displayed on the surfaces of tumor cells in ... (PTTs), derived from proteins that play a role ...
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014   ... and WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials ... Under the terms of the collaboration, Foundation Medicine will ... of Foundation Medicine,s FoundationOne® assay at the WuXi Genome ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5
... Healthy Advice ® Networks, the nation,s ... programs at point-of-care, announces that their partner, MediaForce ... the Food and Drug Administration,s campaign, educating consumers ... relievers. Partnering with MediaForce PR, Healthy Advice ...
... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... meeting of shareholders held in Hong Kong on August 9, ... the re-election of incumbent Class A directors Xiaozhong Liu, Ying ... term. About WuXi PharmaTechWuXi PharmaTech is a ...
Cached Medicine Technology:Healthy Advice® Networks Partners With MediaForce PR to Deliver Public Service Announcements to Educate Consumers About Appropriate Use of Prescription Medications 2Healthy Advice® Networks Partners With MediaForce PR to Deliver Public Service Announcements to Educate Consumers About Appropriate Use of Prescription Medications 3
(Date:10/22/2014)... October 22, 2014 Richard Carlson, Managing ... industry leader with over 25 years experience. Mr. ... in the areas related to EDI, B2B Commerce, RFID ... an Editorial Advisory Board member for Pharmaceutical Commerce Magazine ... Blue Fin Group is a management and technology consulting ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Two sisters in ... heart damage. Ilina and Medha Krishen use electronic ... sounds of trouble in breathing patterns or heartbeats. ... in Michigan, wanted to find a way to detect ... pollutants. Using an electronic stethoscope, Ilina recorded one breath ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, ... tightened guidelines for health workers treating Ebola patients, now requiring ... a respirator at all times. The U.S. Centers for ... after two Dallas nurses contracted Ebola while caring for the ... Thomas Eric Duncan. Nina Pham is currently being treated for ...
(Date:10/20/2014)... Pittsburgh, PA (PRWEB) October 20, 2014 ... new, minimally-invasive procedure that enables physicians to repair a ... , The MitraClip system, developed by ... regurgitation (MR), a progressive and life-threatening condition in which ... allowing blood to flow backward from the heart’s left ...
(Date:10/20/2014)... 20, 2014 T.E.N., a technology ... announced today that William H. Murray, renowned author ... ISE® Luminary Leadership Award winner. Presented annually, the ... an outstanding leader and industry practitioner for his ... advancing the information security industry. , Formerly with ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... from Boston University School of Medicine (BUSM) have ... share the majority of the same genes with ... dysregulate the expression of circadian genes and those ... ,The circadian factors, including the principal circadian hormone ...
... of the anti-malarial drug hydroxychloroquine may help reduce ... diabetes . ,Type 2 diabetes mellitus ... its prevalence has been increasing. ... inexpensive treatment for an autoimmune disease such as ...
... A Canadian researcher has unearthed the relationship between high ... of circumstances , including among individuals with heart disease. ... Montreal Heart Institute, currently affiliated with the Universite de ... typically suffer chest pain during exercise, and may be ...
... admitted that she fears that an innocent kiss will result in ... she has major trust issues, and that she doesn't just make ... a waste of her time and kisses. ,Clarkson added ... ,"I have major trust issues. I just don't make ...
... looming global shortage of phosphorus can be dealt with by ... of the Institute for Sustainable Futures at the University of ... may finish in about 50 years. She believes that if ... a year is recycled, the danger of running out of ...
... ash and smoke into the air, seen in the ... causing more than 8000 people to be evacuated amid ... ,Officials raised the alert to the highest level on Tuesday ... Maluku, started spitting out flaming material, indicating magma was approaching ...
Cached Medicine News:Health News:Cocaine Exposure can Alter Neuronal Development in Zebrafish 2Health News:Anti-malarial Drug may Help Reduce Risk of Diabetes in Rheumatoid Arthritis Patients 2Health News:Urine is a Rich Source of Phosphorus 2Health News:Envisat Captured Breath of Volcano 2
... is a versatile, low profile, titanium ... Minimal instrumentation needed for implantation. Reduction ... Monosegmental and multisegmental applications. Worldwide market ... implantations. Tested in accordance with AS ...
... The ISOLA/VSP Spine System is a comprehensive ... that can be used for both deformity ... understanding of the spine in 3-dimensions, the ... translation techniques to correctly align and stabilize ...
Transcranial and peripheral vascular doppler system....
One channel transcranial doppler with multigate, emboli detection, monitoring module and tests for hemodynamic evaluation. Looki 1TC is suitable as well for routine diagnosis as for monitoring in ope...
Medicine Products: